Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:58 PM
Ignite Modification Date:
2025-12-24 @ 11:58 PM
NCT ID:
NCT01138358
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Diagnosis of advanced disease as defined by the following criteria:
* Lung cancer
* Primary lung cancer at all stages (small cell lung cancer \[SCLC\] and non-small cell lung cancer \[NSCLC\])
* Cancer at any site with secondary tumor of the lung (lung metastasis)
* Chronic obstructive pulmonary disease (COPD)
* Stage III or IV of the Global Initiative for Obstructive Lung Disease (GOLD) classification, which includes the airflow limitation measured by spirometry FEV1 \< 50%, FEV1/FVC \< 0.7, and symptoms such as more severe breathlessness, reduced exercise capacity, and repeated exacerbations
* Chronic heart failure (CHF)
* NYHA class II-IV heart disease, which includes symptoms such as dyspnea or palpitation and an increasing limitation of exercise capacity or discomfort at rest
* Motor neuron disease (MND)
* All patients suffering from breathlessness
* Suffering from episodic breathlessness as defined above at any level of severity
PATIENT CHARACTERISTICS:
* Able to give informed consent
* Able to be interviewed
* No cognitive impairment (clinically judged by the principal investigator)
* No limited comprehension of the English language
PRIOR CONCURRENT THERAPY:
* Concurrent disease-oriented therapies (e.g., chemotherapy, radiotherapy, or surgery) allowed
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01138358
Study Brief:
Protocol Section:
NCT01138358